INVIEW Liquid Biopsy Oncoexome (former GATCLiquid Oncoexome)

INVIEW Liquid Biopsy Oncoexome

Comprehensive profile of all mutations present in the exome

INVIEW Liquid Biopsy Oncoexome is the first non-invasive service to provide researchers and clinicians an overview of all protein- coding regions in the genome of a suspected cancer patient.

The cancer exome sequencing tool offers the opportunity to discover novel variants, recurrent or frequent somatic mutations in circulating tumour DNA (ctDNA) in cases where limited information on tumour-associated genome instability exists.

>> Get Quote / Order

>> order Barcodes

>> Industrial-grade

Applications

Tumour exome analysis of plasma ctDNA from a non-invasive blood test, where tissue biopsy is not feasible or recommended
Examination of all mutations in the coding regions of a suspected cancer patient
Cancer profiling in cases where limited information on tumour-associated mutations is available
Discovery of structural variants, novel and common genomic alterations
Comparison of exomes from tissue biopsy and liquid biopsy samples
Selection of mutations for further analysis

Highlights

Analysis of novel and known tumour mutations in ctDNA based on next-generation sequencing (NGS)
Optimised protocols for low-input ctDNA extraction from plasma
Proprietary workflows for obtaining libraries of high complexity

>> FAQ's Oncoexome

>> Sample Submission

Product Specifications & Ordering

Product details

Full-service package offered by INVIEW Liquid Biopsy Oncoexome includes the following:

Cancer exome sequencing of circulating tumour DNA (ctDNA)
Optimised protocols for library preparation with low duplicate rates
Mutation detection with sensitivity as low as 5% depending on gene loci
Entire process carried out according to ISO 17025

Accepted starting material

Accepted starting material

4 mL plasma sample
15 ng already isolated cell-free DNA (up to 30 µl / concentration > 0,5 ng/µl)

Sequencing technology

Illumina 150 bp paired-end sequencing

Bioinformatics analysis

Faster identification of relevant variants based on curated biological content from the QCI Interpret Translational Knowledge Base
Prioritisation of most promising variants for further analysis

Deliverables

Alignment file (bam)
SNP and InDel tables including annotated variants and effects (vcf, tsv, bed)
Comprehensive Data Analysis Report

Additional Information

Our one-stop Diagnostic Solution for tumour exome sequencing of ctDNA isolated from liquid biopsies offers clinicians and researchers stringent quality assurance throughout the entire process. The product includes a range of pre-sequencing services, starting from ctDNA isolation from low-input samples, to library preparation with reduced duplicate rates, as well as superior exon enrichment and uniform coverage with Agilent’s SureSelect latest chemistry.